Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S, Trippel T, Bach D, Bachran D, González A, López B, Wachter R, Hasenfuss G, Delles C, Dominiczak AF, Pieske B, Díez J, Edelmann F. Ravassa S, et al. Among authors: bach d. Eur J Heart Fail. 2018 Sep;20(9):1290-1299. doi: 10.1002/ejhf.1194. Epub 2018 Apr 30. Eur J Heart Fail. 2018. PMID: 29709099 Free article. Clinical Trial.
Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients.
McGranaghan P, Düngen HD, Saxena A, Rubens M, Salami J, Radenkovic J, Bach D, Apostolovic S, Loncar G, Zdravkovic M, Tahirovic E, Veskovic J, Störk S, Veledar E, Pieske B, Edelmann F, Trippel TD. McGranaghan P, et al. Among authors: bach d. ESC Heart Fail. 2020 Oct;7(5):3029-3039. doi: 10.1002/ehf2.12928. Epub 2020 Aug 28. ESC Heart Fail. 2020. PMID: 32860352 Free PMC article.
Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study.
Herrman JP, Simon R, Umans VA, Peerboom PF, Keane D, Rijnierse JJ, Bach D, Kobi P, Kerry R, Close P, et al. Herrman JP, et al. Among authors: bach d. Eur Heart J. 1995 Nov;16 Suppl L:56-62. doi: 10.1093/eurheartj/16.suppl_l.56. Eur Heart J. 1995. PMID: 8869020 Review.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Olsson T, et al. Among authors: bach d. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. J Neurol Neurosurg Psychiatry. 2014. PMID: 24659797 Free PMC article. Clinical Trial.
Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, Kälebo P, Close P. Eriksson BI, et al. Among authors: bach d. J Bone Joint Surg Am. 1997 Mar;79(3):326-33. doi: 10.2106/00004623-199703000-00002. J Bone Joint Surg Am. 1997. PMID: 9070519 Clinical Trial.
Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N. Macdonald RL, et al. Among authors: bach d. Lancet Neurol. 2011 Jul;10(7):618-25. doi: 10.1016/S1474-4422(11)70108-9. Epub 2011 Jun 2. Lancet Neurol. 2011. PMID: 21640651 Clinical Trial.
694 results